<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72782">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02158195</url>
  </required_header>
  <id_info>
    <org_study_id>AUDIA APJ 2012</org_study_id>
    <nct_id>NCT02158195</nct_id>
  </id_info>
  <brief_title>Immunopathology of Autoimmune Hemolytic Anemia</brief_title>
  <acronym>IAHAI</acronym>
  <official_title>Immunopathology of Autoimmune Hemolytic Anemia. Open, Prospective, Multicentre Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      The aim of this study is to compare different blood cells of the immune response in patients
      with Autoimmune Hemolytic Anemia and healthy subjects.

      Evaluate the impact of treatments, notably corticoids, on blood cells of the immune
      response.

      Better understanding of the mechanisms involved in the course of this disease could lead to
      new treatments.

      12 patients with Autoimmune Hemolytic Anemia will be compared with 12 controls matched for
      sex and age.

      Controls will provide blood samples only once. The will have no particular follow-up.

      Patients will provide blood samples at the time of diagnosis then 3 months after the start
      of treatment. If a new treatment needs to be started before the end of the 3-month period, a
      new blood sample will be taken.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood level and the percentage of Treg (CD4 + CD25HighFoxp3 +)</measure>
    <time_frame>Change from baselines blood level and the percentage of Treg at 3 months treatment with corticoids</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of inhibition of proliferation of Treg</measure>
    <time_frame>Change from baselines percentage of inhibition of proliferation of Treg at 3 months treatment with corticoids</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Autoimmune Hemolytic Anemia</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with warm primary or secondary Autoimmune Hemolytic Anemia
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with primary warm Autoimmune Hemolytic Anemia

          -  Secondary Autoimmune Hemolytic Anemia (infections, hemopathy, systemic diseases)

          -  Naive to any treatment for hemolytic anemia or in relapse

          -  Older than 16 years of age

          -  Able to understand written and spoken French

          -  who have provided written informed consent

             • INCLUSION CRITERIA for CONTROLS

          -  Persons without an auto-immune disease, or cancer or an active infection.

          -  Older than 16 years of age

          -  Able to understand written and spoken French

          -  who have provided written informed consent

        Exclusion Criteria:

          -  Cold agglutinin disease

          -  Pregnant women

          -  Persons not covered by national health insurance

        Non-Inclusion Criteria controls:

          -  Persons treated with corticoids or immunosuppressants

          -  Pregnant women

          -  Persons not covered by national health insurance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sylvain AUDIA</last_name>
    <phone>3.80.29.34.32</phone>
    <phone_ext>+33</phone_ext>
    <email>sylvain.audia@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric DECONINCK</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Chalon-sur-Saône</name>
      <address>
        <city>Chalon-sur-Saône</city>
        <zip>71100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno SALLES</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain AUDIA</last_name>
      <phone>3.80.29.34.32</phone>
      <phone_ext>+33</phone_ext>
      <email>sylvain.audia@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de METZ</name>
      <address>
        <city>Metz</city>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François MAURIER</last_name>
      <phone>3 87 39 47 72</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Mâcon</name>
      <address>
        <city>Mâcon</city>
        <zip>71018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Géraldine RAICHON PATRU</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>June 5, 2014</lastchanged_date>
  <firstreceived_date>March 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
